The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
Wuerstlein, R, Sotlar, K, Gluz, O, Otremba, B, von Schumann, R, Witzel, I, Schindlbeck, C, Janni, W, Schem, C, Bauerfeind, I, Hasmueller, S, Tesch, H, Paulenz, A, Ghali, N, Orujov, E, Kates, R E, Cowens, W, Hornberger, J, Pelz, E, Harbeck, N
Published in Current medical research and opinion (02.07.2016)
Published in Current medical research and opinion (02.07.2016)
Get more information
Journal Article
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus, V., Jackisch, C., Lück, H.J., du Bois, A., Thomssen, C., Kuhn, W., Nitz, U., Schneeweiss, A., Huober, J., Harbeck, N., von Minckwitz, G., Runnebaum, I.B., Hinke, A., Konecny, G.E., Untch, M., Kurbacher, C.
Published in Annals of oncology (01.01.2018)
Published in Annals of oncology (01.01.2018)
Get full text
Journal Article
Abstract P5-07-03: Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study
Wuerstlein, R, Sotlar, K, Gluz, O, Hofmann, D, Otremba, B, Von Schumann, R, Witzel, I, Schindlbeck, C, Janni, W, Schem, C, Bauerfeind, I, Hasmueller, S, Tesch, H, Paulenz, A, Morel, P, Cowens, W, Hornberger, J, Kates, RE, Pelz, E, Harbeck, N
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer
Sehouli, J., Sommer, H., Klare, P., Stauch, M., Zeimet, A., Paulenz, A., Steck, T., Riedel, H., Keil, E., Stengel, D., Kuznik, A., Lichtenegger, W.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer
Oskay-Özcelik, G., Sehouli, J., Sommer, H., Klare, P., Stauch, M., Zeimet, A., Paulenz, A., Renziehausen, K., Keil, E., Lichtenegger, W.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer
Oskay-Özcelik, G., Sehouli, J., Sommer, H., Klare, P., Stauch, M., Zeimet, A., Paulenz, A., Renziehausen, K., Keil, E., Lichtenegger, W.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Die prospektive, multizentrische WSG-BCIST Decision Impact Studie beim postmenopausalen ER+ HER2- N0 frühen Mammakarzinom unterstützt die molekulare Testung für intrinsischen Subtypen
Würstlein, R, Sotlar, K, Gluz, O, Hofmann, D, Otremba, B, Schumann, R von, Witzel, I, Schindlbeck, C, Janni, W, Schem, C, Bauerfeind, I, Hasmüller, S, Tesch, H, Paulenz, A, Morel, P, Cowens, W, Hornberger, J, Kates, R, Pelz, E, Harbeck, N
Published in Senologie - Zeitschrift für Mammadiagnostik und -therapie (22.05.2015)
Published in Senologie - Zeitschrift für Mammadiagnostik und -therapie (22.05.2015)
Get full text
Conference Proceeding